Investigating how brain insulin affects glucose metabolism after meals
Relative Contribution of Brain Insulin Action for Postprandial Metabolism
NA · University of Ulm · NCT06295640
This study is testing whether using insulin in the nose can help people manage their blood sugar levels after meals and if this effect is different for men and women.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Sponsor | University of Ulm (other) |
| Locations | 1 site (Ulm) |
| Trial ID | NCT06295640 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to clarify the role of brain insulin action in regulating systemic metabolism, particularly focusing on postprandial glucose metabolism. Participants will undergo oral glucose tolerance tests while receiving either intranasal insulin or a placebo, allowing researchers to compare the effects of brain insulin on metabolic control. The study will also explore sex-specific differences and the influence of the menstrual cycle on these processes. By utilizing a double tracer dilution technique, the research will assess endogenous glucose production and the rates of glucose disappearance during the tests.
Who should consider this trial
Good fit: Ideal candidates are individuals with a BMI less than 24 kg/m2, without known primary diseases or hormonal contraception.
Not a fit: Patients with alcohol or drug abuse issues, smoking habits, or certain clinical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of metabolic disorders and lead to improved treatments for glucose metabolism issues.
How similar studies have performed: While the specific approach of this study is novel, previous research has indicated the importance of insulin action in metabolic regulation, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI \< 24 kg/m2 * no known primary diseases * no hormonal contraception Exclusion Criteria: * Alcohol or drug abuse * Smoking * At screening: Hb \< 12 g/dl for women and Hb \< 14 g/dl for men * Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.
Where this trial is running
Ulm
- Universityhospital Ulm — Ulm, Germany (RECRUITING)
Study contacts
- Principal investigator: Martin Heni, MD — University of Ulm
- Study coordinator: Martin Heni, MD
- Email: martin.heni@uniklinik-ulm.de
- Phone: +4973150044505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glucose Metabolism Disorders, postprandial glucose metabolism, brain insulin action, insulin sensitivity, insulin secretion, endogenous glucose production, menstrual cycle, sex differences